The National Pregnancy Registry for ADHD Medications is seeking pregnant women between the ages of 18 and 45.

This Massachusetts General Hospital Center for Women’s Mental Health research study will involve 3 brief phone interviews over an 8-month period.

The National Pregnancy Registry for ADHD Medications is dedicated to evaluating the safety of ADHD medications that may be taken by women during pregnancy to treat a wide range of attention, mood, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to these medications during pregnancy.  You do not need to be taking an ADHD medication to enroll in this study, although you must have a history of psychiatric illness.

For more information, please call 1-866-961-2388.

More Information and Enrollment:

All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry. If you are interested in participating in the National Pregnancy Registry, please call the toll-free number above or fill out this Patient Interest Form to be contacted by a member of our research team. All information is kept strictly confidential.

More Information and Enrollment:

Call Toll-Free: 1-866-961-2388

Required Sponsorship Disclosures:

Current Sponsors: Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).

Past Sponsors: Forest/Actavis (2016-2018, declined to sponsor: 2018-Present), AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present)

Declined to sponsor: Eli Lilly and Company; Novartis Pharmaceuticals; Vanda Pharmaceuticals Inc.

Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.